KCM Investment Advisors LLC Sells 3,265 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

KCM Investment Advisors LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,592 shares of the medical research company's stock after selling 3,265 shares during the quarter. KCM Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $3,429,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Thermo Fisher Scientific by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock valued at $5,972,000 after acquiring an additional 995 shares in the last quarter. Greenwood Gearhart Inc. raised its stake in shares of Thermo Fisher Scientific by 9.8% in the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after purchasing an additional 1,837 shares during the last quarter. Nordea Investment Management AB grew its holdings in Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after buying an additional 10,606 shares in the last quarter. Finally, S.E.E.D. Planning Group LLC raised its holdings in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after purchasing an additional 618 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Up 0.9 %

TMO traded up $3.68 during trading on Friday, hitting $431.12. 846,944 shares of the company's stock traded hands, compared to its average volume of 1,688,335. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company's 50 day simple moving average is $513.41 and its two-hundred day simple moving average is $540.46. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $162.65 billion, a price-to-earnings ratio of 26.09, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on TMO. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Wells Fargo & Company upped their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.